ATNM Actinium Pharmaceuticals Inc: Net earnings per one share for the last twelve months

Actinium Pharmaceuticals (ATNM) is recognized as an authoritative developer of radiotherapy for combating hematological tumors, a position highly valued by physicians. Company management enjoys strong trust due to successful final trials and preparations for commercial sales. The business relies on the B2B segment of oncology centers, helping leukemia patients prepare for bone marrow transplants. This price chart reflects an EPS of 130.60.
actiniumpharma.com - analytical breakdowns and key metrics (ATNM)

This indicator measures the dynamics of net earnings per share over a rolling year, allowing for the differentiation of true business growth from short-term market anomalies. By analyzing the current EPS YoY shift over the last 12 months, an investor can assess the capital management efficiency of Actinium Pharmaceuticals (ATNM) and the transparency of clinical strategy implementation in radiotherapy through the lens of actual profitability.